2022, 2(4): 225-243.
doi: 10.2478/fzm-2022-0030
Keywords:
diabetes mellitus ,
type 2 diabetes mellitus ,
anti-diabetic drugs ,
therapeutic target ,
glycemic control ,
insulin resistance ,
deficient insulin secretion ,
diabetic complications ,
polypharmacology
Diabetes mellitus (DM) is a progressive metabolic disease characterized by chronic hyperglycemia and caused by different degree of pancreatic islet dysfunction and/or insulin resistance (IR). Long course DM can lead to a variety of macrovascular and microvascular complications which involve artery vessels, heart, kidney, retina, nervous system, etc. In recent years, DM has attracted more and more attention due to its high morbidity and mortality. In addition to achieve effective glycemic control, prevention of complications has also been considered a priority for type 2 diabetes mellitus (T2DM) management. Herein, we provide a comprehensive overview on the pharmacotherapeutics for T2DM and perspectives on the future directions of basic and translational research on anti-diabetic therapy and pharmatheutical development of new drugs.
2022, 2(1): 53-64.
doi: 10.2478/fzm-2022-0007
Keywords:
non-small cell lung cancer ,
apelin ,
yes associated protein 1 ,
epithelial-mesenchymal transition
2021, 1(1): 3-8.
doi: 10.2478/fzm-2021-0002
Hypertension is the most common cardiovascular condition in clinical practice and a major risk factor for stroke and cardiovascular events. There are more than 270 million hypertension patients in China, and the prevalence of hypertension in the high-latitude cold areas is significantly higher than in the low-latitude warm areas. The unique epidemiological characteristics and risk factors of hypertension in the cold regions of China urge for establishment of the prevention and control system for targeted and more effective management of the condition.
2024, 4(1): 51-64.
doi: 10.2478/fzm-2024-0006
2024, 4(1): 41-50.
doi: 10.2478/fzm-2024-0005